Seeking Alpha

FDA reviewer Nancy Xu says Cornerstone's (CRTX +5.3%) Lixivaptan drug should be approved to...

FDA reviewer Nancy Xu says Cornerstone's (CRTX +5.3%) Lixivaptan drug should be approved to treat low sodium levels in the blood due to a condition that causes the body to have excess water. However, Xu says Lixivaptan shouldn't be authorized for heart-failure patients. An FDA advisory panel is due to meet on Thursday.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|